Preparation of agents that can successfully traverse the blood-brain-barrier (BBB) is a key challenge in
brain cancer therapeutics. In this study,
angiopep-2 was used as a brain-targeting
peptide for preparing multifunctional Angiopep-2-modified poly nanoparticles,
angiopep-2 and IP10-EGFRvIIIscFv fusion
protein modified nanoparticles. In vitro experiments showed a greater uptake of
Angiopep-2 modified nanoparticles, also
angiopep-2 and IP10-EGFRvIIIscFv fusion
protein modified nanoparticles by bEnd.3 cells versus nanoparticles and nanoparticles modified by IP10-EGFRvIIIscFv.
Angiopep-2 and IP10-EGFRvIIIscFv fusion
protein modified nanoparticles accumulated in brain tissue after
intravenous injection and recruited activated CD8+ T lymphocytes to location of
glioblastoma cells. In vivo experiments to assess anti-
glioblastoma effect of
angiopep-2 and IP10-EGFRvIIIscFv fusion
protein modified nanoparticles showed significantly reduced
tumor volume in
angiopep-2 and IP10-EGFRvIIIscFv fusion
protein modified nanoparticles+ CD8+ cytotoxic T lymphocytes group versus in NPs modified by IP10-EGFRvIIIscFv+ CD8+ cytotoxic T lymphocytes, CD8+ cytotoxic T lymphocytes,
Angiopep-2 modified nanoparticles+ CD8+ cytotoxic T lymphocytes,
angiopep-2 and IP10-EGFRvIIIscFv fusion
protein modified nanoparticles and PBS groups. Leukocytes infiltrated in brain tissues showed strong anti-
glioblastoma activity in
angiopep-2 and IP10-EGFRvIIIscFv fusion
protein modified nanoparticles+ CD8+ cytotoxic T lymphocytes treated mice. Thus,
angiopep-2 and IP10-EGFRvIIIscFv fusion
protein modified nanoparticles may be useful for brain-targeted delivery and recruitment of activated CD8+ T lymphocytes to
glioblastoma cells.